Summit Therapeutics Inc.
SMMTNasdaqCIK 1599298HealthcareFiscal year ends Dec 31
Reports and events: 309 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-1911:01 ET | DEF 14A | Proxy statementPeriod 2026-11-04 | 0001193125-26-424642 |
| 2026-09-2901:39 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-405776 |
| 2026-09-1512:44 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-26-000081 |
| 2026-09-1412:37 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-26-000078 |
| 2026-09-0313:21 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-26-000076 |
| 2026-08-2613:17 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-26-000074 |
| 2026-08-0511:32 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-26-000071 |
| 2026-07-2320:34 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-314214 |
| 2026-07-2320:08 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001599298-26-000068 |
| 2026-07-2320:07 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001599298-26-000067 |
| 2026-07-2211:10 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-26-000058 |
| 2026-06-1220:11 ET | 8-K | 5.07 Shareholder vote results | 0001599298-26-000054 |
| 2026-06-1111:44 ET | 8-K | 7.01 Regulation FD disclosure | 0001599298-26-000052 |
| 2026-06-0312:01 ET | 8-K | 8.01 Other events | 0001599298-26-000049 |
| 2026-06-0110:57 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-26-000043 |
| 2026-04-3021:00 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001599298-26-000039 |
| 2026-04-3020:40 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001599298-26-000037 |
| 2026-04-1720:12 ET | DEF 14A | Proxy statementPeriod 2026-04-17 | 0001599298-26-000029 |
| 2026-02-2321:10 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001599298-26-000015 |
| 2026-02-2321:07 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001599298-26-000014 |
| 2026-01-2912:35 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-26-000006 |
| 2026-01-1212:43 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001599298-26-000004 |
| 2025-11-0714:23 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-25-000166 |
| 2025-10-2212:56 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-245790 |
| 2025-10-2011:51 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001599298-25-000159 |
| 2025-10-2011:28 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-25-000156 |
| 2025-09-0811:45 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-25-000137 |
| 2025-08-1121:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001599298-25-000128 |
| 2025-08-1120:51 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-25-178022 |
| 2025-08-1120:23 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001599298-25-000126 |
| 2025-06-2021:07 ET | 8-K | 1.01 Entry into a material agreement | 0001599298-25-000120 |
| 2025-06-1720:13 ET | 8-K | 5.07 Shareholder vote results | 0001599298-25-000116 |
| 2025-05-3020:17 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-25-000099 |
| 2025-05-0120:11 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001599298-25-000089 |
| 2025-05-0120:10 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001599298-25-000088 |
| 2025-04-2920:44 ET | DEF 14A | Proxy statementPeriod 2025-06-12 | 0001599298-25-000075 |
| 2025-04-2520:38 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-25-000066 |
| 2025-04-2312:54 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-25-000064 |
| 2025-02-2411:53 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001599298-25-000048 |
| 2025-02-2411:08 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001599298-25-000044 |
| 2025-01-2421:23 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events | 0001599298-25-000038 |
| 2025-01-1313:37 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001599298-25-000034 |
| 2024-10-3011:33 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001599298-24-000158 |
| 2024-10-3011:06 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001599298-24-000156 |
| 2024-09-1321:54 ET | SC 13D/A | Ownership report, active investor, amended | 0001193125-24-218980 |
| 2024-09-1210:49 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-217618 |
| 2024-09-0911:23 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-24-000128 |
| 2024-08-0611:37 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001599298-24-000117 |
| 2024-08-0611:14 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001599298-24-000113 |
| 2024-06-2720:27 ET | 8-K | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001599298-24-000103 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.